An open-label, single-arm, single-center, dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of ABOR2013 monotherapy or in combination with PD-1 monoclonal antibody(Sintilimab) in advanced non-small cell lung cancer (NSCLC) patients carrying at least one activating EGFR mutation (L858R/19del[E746_A750del]/T790M).
100 项与 ABOR-2013 相关的专利(医药)